Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$449.2m

Esperion Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ESPR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Dec 24SellUS$5,426Eric WarrenIndividual2,234US$2.43
17 Dec 24SellUS$7,866Benjamin HalladayIndividual3,245US$2.42
17 Dec 24SellUS$30,694Sheldon KoenigIndividual12,447US$2.47
19 Nov 24SellUS$427Eric WarrenIndividual197US$2.17
17 Oct 24SellUS$227Eric WarrenIndividual107US$2.12
17 Sep 24SellUS$4,650Eric WarrenIndividual2,608US$1.78
17 Sep 24SellUS$26,132Sheldon KoenigIndividual14,550US$1.80
19 Aug 24SellUS$411Eric WarrenIndividual211US$1.95
17 Jul 24SellUS$2,383JoAnne FoodyIndividual917US$2.60
17 Jul 24SellUS$279Eric WarrenIndividual108US$2.59
18 Jun 24SellUS$7,254Eric WarrenIndividual2,540US$2.86
18 Jun 24SellUS$9,418JoAnne FoodyIndividual3,285US$2.87
17 May 24SellUS$477Eric WarrenIndividual192US$2.48

Insider Trading Volume

Insider Buying: ESPR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ESPR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,502,2650.762%
General Public64,052,96332.5%
Institutions131,479,94366.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.3%.

Top Shareholders

Top 25 shareholders own 58.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.9%
Wasatch Advisors LP
23,346,013US$53.2m38.5%0.17%
7.24%
BlackRock, Inc.
14,264,975US$32.5m2.01%no data
6.62%
The Vanguard Group, Inc.
13,043,077US$29.7m20.6%no data
5.05%
Bellevue Asset Management AG
9,944,064US$22.7m0%0.28%
3.34%
Two Seas Capital LP
6,584,278US$15.0m14.8%2.33%
2.2%
Geode Capital Management, LLC
4,331,314US$9.9m4.13%no data
1.96%
State Street Global Advisors, Inc.
3,854,314US$8.8m2.66%no data
1.92%
Meditor Group Ltd.
3,791,300US$8.6m0%4.8%
1.84%
Two Sigma Investments, LP
3,625,059US$8.3m-11%0.02%
1.83%
Two Sigma Advisers, LP
3,600,100US$8.2m-7.08%0.02%
1.73%
Millennium Management LLC
3,403,530US$7.8m-47.8%0.01%
1.58%
Centerbook Partners LP
3,112,585US$7.1m98.3%0.43%
1.57%
Marshall Wace LLP
3,092,629US$7.1m-28.1%0.01%
1.27%
Morgan Stanley, Investment Banking and Brokerage Investments
2,506,415US$5.7m-21.5%no data
1.14%
Woodline Partners LP
2,244,360US$5.1m-55.6%0.05%
1.06%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
2,093,682US$4.8m-7.84%no data
1%
Rhenman & Partners Asset Management AB
1,975,000US$4.5m0%0.33%
0.79%
Deutsche Asset & Wealth Management
1,560,072US$3.6m1.82%no data
0.75%
Northern Trust Global Investments
1,474,422US$3.4m264%no data
0.69%
JP Morgan Asset Management
1,355,910US$3.1m1.17%no data
0.63%
Goldman Sachs Group, Investment Banking and Securities Investments
1,251,139US$2.9m36.6%no data
0.56%
Bank of America Corporation, Asset Management Arm
1,110,154US$2.5m-3.47%no data
0.55%
Platinum Investment Management Limited
1,092,862US$2.5m-8.66%0.09%
0.46%
Renaissance Technologies LLC
914,100US$2.1m-35.7%no data
0.46%
Parkman Healthcare Partners LLC
903,140US$2.1m-21.1%0.29%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 13:08
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Esperion Therapeutics, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Thomas ShraderBTIG
Kristen KluskaCantor Fitzgerald & Co.